Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome

Adrian R. Levy, Peter Chen, Karissa Johnston, Yan Wang, Evan Popoff, Ioannis Tomazos

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)
Original languageEnglish
Pages (from-to)249-259
Number of pages11
JournalJournal of Medical Economics
Volume25
Issue number1
DOIs
Publication statusPublished - 2022
Externally publishedYes

ASJC Scopus Subject Areas

  • Health Policy

Keywords

  • aHUS treatment
  • caregiver productivity
  • cost minimization model
  • lost productivity
  • ravulizumab

Fingerprint

Dive into the research topics of 'Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome'. Together they form a unique fingerprint.

Cite this